Head-To-Head Comparison: Exelixis (NASDAQ:EXEL) and Rein Therapeutics (NASDAQ:RNTX)

Exelixis (NASDAQ:EXEL) and Rein Therapeutics (NASDAQ:RNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Exelixis and Rein Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2	11	9	1	2.39
Rein Therapeutics	1	1	1	0	2.00

Exelixis currently has a consensus target price of $47.35, suggesting a potential downside of 6.19%. Rein Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 620.72%. Given Rein Therapeutics’ higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Exelixis.

Profitability

This table compares Exelixis and Rein Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Rein Therapeutics	N/A	-510.35%	-68.14%

Volatility and Risk

Exelixis has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Earnings & Valuation

This table compares Exelixis and Rein Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32 billion	5.47	$782.57 million	$3.01	16.77
Rein Therapeutics	N/A	N/A	-$49.87 million	($1.90)	-0.58

Exelixis has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Exelixis beats Rein Therapeutics on 10 of the 14 factors compared between the two stocks.

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

About Rein Therapeutics

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.